CorMedix Inc - Asset Resilience Ratio
CorMedix Inc (CRMD) has an Asset Resilience Ratio of 0.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CRMD total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how CorMedix Inc's Asset Resilience Ratio has changed over time. See CRMD book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CorMedix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CRMD stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.22 Million | 0.96% |
| Total Liquid Assets | $7.22 Million | 0.96% |
Asset Resilience Insights
- Limited Liquidity: CorMedix Inc maintains only 0.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CorMedix Inc Industry Peers by Asset Resilience Ratio
Compare CorMedix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for CorMedix Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for CorMedix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.29% | $11.04 Million | $118.85 Million | -30.18pp |
| 2023-12-31 | 39.47% | $32.39 Million | $82.06 Million | +14.25pp |
| 2022-12-31 | 25.22% | $15.64 Million | $62.04 Million | +7.60pp |
| 2021-12-31 | 17.62% | $12.15 Million | $68.95 Million | +8.61pp |
| 2020-12-31 | 9.01% | $4.44 Million | $49.31 Million | -31.64pp |
| 2019-12-31 | 40.66% | $11.98 Million | $29.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $18.83 Million | -- |
| 2017-12-31 | 11.92% | $1.60 Million | $13.45 Million | -43.32pp |
| 2016-12-31 | 55.24% | $12.10 Million | $21.91 Million | -8.28pp |
| 2015-12-31 | 63.52% | $23.57 Million | $37.10 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $5.10 Million | -- |
| 2013-12-31 | 7.45% | $221.00K | $2.97 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.15 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.56 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more